FDA accepts OP-1 implant filing:
This article was originally published in Clinica
Stryker's premarket approval (PMA) application for its orthopaedic tissue engineering product OP-1 Implant has been accepted by the US FDA. The implant combines the bone growth factor OP-1 with type 1 bone collagen as an alternative to painful bone autografts for non-union fractures. Stryker filed the PMA last month following a series of delays caused by regulatory changes and the integration of manufacturing facilities for OP-1 (see Clinica No 862, p 19).
You may also be interested in...
Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.